Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corever in hypertension
NCT02432937Phase 3Completed
- Sponsor
- TSH Biopharm Corporation Limited
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of carvedilol in hypertension (HTN) (3 arms), sponsored by TSH Biopharm Corporation Limited. Primary endpoint: Seated Office Systolic Blood Pressure Reduction at 8 weeks. Started Jan 2015; status: completed.
02
Drugs
carvedilol
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02432937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432937.